brtxDISC™ (Disc Implanted Stem Cells)
is an investigational non-surgical treatment for bulging and herniated
lumbar discs that is intended for patients who have failed
non-invasive procedures and face the prospect of surgery. The
treatment involves culturing a patient’s own stem cells and then
delivering them via a proprietary medical device to the damaged region
of the disc in an outpatient procedure.
ThermoStem® is a treatment using brown fat stem cells that is
under development for metabolic disorders including diabetes and
obesity. Initial preclinical research indicates that increased amounts
of brown fat in the body may be responsible for additional caloric
burning as well as reduced glucose and lipid levels.
brtx-C Cosmetic is based on the development of a human cellular
extract that has been demonstrated in in vitro skin studies to
increase the production of collagen and fibronectin, which are
proteins that are essential to combating the aging of skin. Potential
cosmetic uses are being explored with third parties.
JUPITER, Fla.--(BUSINESS WIRE)--
BioRestorative Therapies, Inc. ("BRT" or the "Company")(OTCBB: BRTX), a life sciences company focused on adult stem
cell-based cellular therapies for various personal medical applications,
today announced the appointment of Joseph B. Swiader, age 54, to its
Board of Directors. Mr. Swiader will chair the Nominating Committee and
serve on the Compensation Committee of the Board.
Mr. Swiader has extensive experience in both the financial and
biotechnology sectors. He is currently managing partner of Wet Earth
Partners LLC, which he founded in 2002. Wet Earth Partners invests in a
range of ventures that include biotechnology, medical technology and
consumer products. Previously he was a partner at Feirstein Capital
Management, where he oversaw investments in biotechnology,
pharmaceutical, medical technology and healthcare services companies.
Earlier Mr. Swiader was the Senior Global Healthcare Analyst at Scudder,
Stevens & Clark (now part of Deutsche Asset & Wealth Management). Mr.
Swiader was also a biotechnology and pharmaceutical analyst for the
Dreyfus group of funds. He began his investment career in 1992 as a
biotechnology analyst at JP Morgan Securities.
“As we advance our technologies through the regulatory pathway and
position BioRestorative Therapies for growth, we have focused on
deepening our corporate leadership and governance,” said Mark Weinreb,
Chief Executive Officer of BioRestorative Therapies. “Joe will provide a
wealth of valuable experience in both finance and biotechnology, and we
are very pleased he has agreed to join our Board of Directors.”
Mr. Swiader received a Bachelor of Science degree in finance from Babson
College in 1992.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com)
develops products and medical procedures using cell and tissue
protocols, primarily involving adult stem cells, including:
The Company also offers plant stem cell-based facial creams and beauty
products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the Company undertakes no obligation to
update such statements.
Kim Sutton Golodetz, 212-838-3777
Source: BioRestorative Therapies, Inc.